In this article, we reviewed multiple pediatric and AYA precision medicine trials to highlight the dysregulation of the CDK4/6 cell cycle regulatory pathway in the most common types of pediatric and AYA sarcomas, as well as to provide insight into the promise and challenges of targeting the CDK4/6 pathway. Here, CDK4 is linked to sarcoma.